1-3 of 3
Shani M. Wilbur, BS
Close
Sort by
Journal Articles

Conventional and Pretargeted Radioimmunotherapy with Bismuth-213 to Target and Treat CD20-Expressing Non-Hodgkin Lymphoma: A Preclinical Model for Consolidation Therapy to Eradicate Minimal Residual Disease.

Steven I. Park, MD, Jaideep Shenoi, MD, John M. Pagel, MD, PhD, Donald K. Hamlin, Nural Orgun, Aimee L. Kenoyer, Shani M. Wilbur, BS, Amanda Axtman, D. Scott Wilbur, PhD, Yukang Lin, PhD, Darrell R. Fisher, PhD, Ajay K. Gopal, MD, Damian J. Green, MD, Oliver W. Press, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 2705.
https://doi.org/10.1182/blood.V114.22.2705.2705
Published: 2009
Journal Articles

Anti-CD45 Ab Pretargeted Radioimmunotherapy Using An Alpha Emitting Radionuclide (213Bi) Delivers Selective Radiation to Human Myeloid Leukemias in a Mouse Xenograft Model and Results in High Rates of Complete Remission and Long Term Survival.

Aimee L. Kenoyer, BS, Oliver W. Press, MD, PhD, Steven I. Park, MD, Tom Back, Donald K. Hamlin, BS, D. Scott Wilbur, PhD, Darrell R. Fisher, PhD, Shani M. Wilbur, BS, Amanda Axtman, BS, Nural Orgun, Yukang Lin, PhD, Ajay K. Gopal, MD, Jaideep Shenoi, MD, Damian J. Green, MD, Frederick R Appelbaum, John M. Pagel, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 1035.
https://doi.org/10.1182/blood.V114.22.1035.1035
Published: 2009
Journal Articles

Rituximab Blocks Binding of Radiolabeled Anti-CD20 Antibodies (Ab) but Not Radiolabeled Anti-CD45-Ab.

Ajay K. Gopal, MD, Oliver W. Press, MD, PhD, Shani M. Wilbur, BS, David G. Maloney, MD, PhD, John M. Pagel, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 525.
https://doi.org/10.1182/blood.V110.11.525.525
Published: 2007